PA-PMI
22.8.2022 14:02:14 CEST | Business Wire | Press release
Project Management Institute (PMI) today announced that its Board of Directors has named Pierre Le Manh as President and Chief Executive Officer (CEO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005706/en/
Starting September 1, Pierre Le Manh, a veteran CEO of professional services and knowledge industries, will lead PMI’s fast-growing global organization and oversee the continued execution of PMI’s Impact Strategy. In his role, Pierre will also serve as the lead advocate for PMI’s global organization and close to a hundred million project professionals worldwide.
“We are very excited to bring Pierre Le Manh on board after a thorough selection process,” said Jennifer Tharp, PMP, Chair of PMI’s Board of Directors. “We have big ambitions for the future of our profession and the Project Management Institute as a leading global organization. Pierre brings the global experience and credentials to accelerate PMI’s current business and further our innovation and transformation journey. As Michael DePrisco will resume his responsibilities as PMI’s chief operating officer, the Board and myself want to express our gratitude to Michael for serving as interim CEO during the selection process.”
Pierre Le Manh has served in CEO roles for over 20 years at knowledge, research, and technology-based companies worldwide. He has lived and worked in Paris, Montreal, London, Rome, and New York City. He brings a proven track record of growth, transformation, and globalization and a passion for team building and nurturing culture.
“Think about what project professionals have achieved across all sectors of the economy and society: from construction to technology, from healthcare to government, from consumer goods to infrastructure, from arts to sciences,” said Le Manh. “Maybe even more importantly, think of the daunting tasks ahead of them when humanity has no other choice than to pursue more sustainable development in the future. Without competent professionals to lead and run projects, ideas cannot be made a reality. Project professionals are the doers and builders of transformation.”
“I am eager to work with PMI’s Board, Michael DePrisco and the leadership team, and our growing global team of more than 700 permanent employees to take on the challenges of a new era, innovate and build upon PMI’s status as a fast-growing global leader in professional development, education, and upskilling,” continued Le Manh. “I enthusiastically look forward to meeting and working with the greater global mission-driven community of changemakers of more than 300 chapters, 10,000 volunteers, and close to 700,000 active PMI members to create better outcomes for individuals, businesses, and society worldwide.”
Before joining PMI, Pierre Le Manh recently led a project for the North American expansion of Galileo Global Education, a European leader in post-secondary higher education and education technology. Until 2021, he served as the Chief Executive Officer of North America and Global Deputy CEO of Ipsos, the global leader in market research and data analytics, where he played a key leadership role in the company’s global expansion for over 15 years, first as CEO for EMEA and then as global head of several professional practices before heading the North American business. Before Ipsos, he held several other CEO positions in technology-based services and publishing.
“I am very excited to leverage the broad and deep experience I have gained over my career to lead the PMI organization and, in particular, to create a stronger membership experience for project professionals seeking lifelong learning and development opportunities and for corporate partners investing in reskilling and upskilling their workforce,” Le Manh said.
About Project Management Institute (PMI)
Project Management Institute (PMI) is the leading professional development organization for project management and the authority for a growing global community of millions of professionals of the project economy who use project, program, and portfolio management skills and competencies.
Building on a proud legacy dating to 1969, PMI is a not-for-profit for-purpose organization working in nearly every country to advance careers, strengthen organizational success, and enable project professionals and changemakers with new skills and ways of working to maximize their impact. PMI offerings include globally recognized standards, certifications, online courses, thought leadership, tools, digital publications, and communities.
PMI empowers people to make ideas a reality and helps professionals and changemakers create better outcomes for businesses, communities, and society worldwide. Through global advocacy, networking, collaboration, research, and education, PMI prepares organizations and individuals at every stage of their career journey to work smarter to drive success in a world of change.
Visit us at www.PMI.org , LinkedIn , https://www.facebook.com/PMInstitute , and on Twitter @PMInstitute .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005706/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom